869557-28-8

Basic information

• Product Name: 3-Pyridinecarbonitrile, 2-amino-5-chloro-
• Synonyms: 3-Pyridinecarbonitrile, 2-amino-5-chloro-;2-AMino-5-chloronicotinonitrile
• CAS NO: 869557-28-8
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.57
• Mol File: 869557-28-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: 3-Pyridinecarbonitrile, 2-amino-5-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarbonitrile, 2-amino-5-chloro-(869557-28-8)
• EPA Substance Registry System: 3-Pyridinecarbonitrile, 2-amino-5-chloro-(869557-28-8)

Safety Data

• Hazardous Substances Data: 869557-28-8(Hazardous Substances Data)

Usage

General Description

3-Pyridinecarbonitrile, 2-amino-5-chloro- is a chemical compound with the molecular formula C6H4ClN3. It is a derivative of pyridine and contains a chloro and an amino group. 3-Pyridinecarbonitrile, 2-amino-5-chloro- is commonly used in organic synthesis and pharmaceutical research as a building block for the development of various drugs and chemical compounds. It has also been studied for its potential biological activities and is of interest in the field of medicinal chemistry. Its unique structure and properties make it a valuable intermediate in the production of a variety of chemical and pharmaceutical products.

Upstream product

• 557-21-1 zinc(II) cyanide 
• 26163-03-1 2-amino-3-bromo-5-chloropyridine 
• 557-21-1 dicyanozinc 

Relevant articles and documents

Discovery of a Novel Highly Selective Histamine H4 Receptor Antagonist for the Treatment of Atopic Dermatitis

The histamine H4 receptor (H4R), a member of the G-protein coupled receptor family, has been considered as a potential therapeutic target for treating atopic dermatitis (AD). A large number of H4R antagonists have been disclosed, but no efficient agents controlling both pruritus and inflammation in AD have been developed yet. Here, we have discovered a novel class of orally available H4R antagonists showing strong anti-itching and anti-inflammation activity as well as excellent selectivity against off-targets. A pharmacophore-based virtual screening system constructed in-house successfully identified initial hit compound 9, and the subsequent homology model-guided optimization efficiently led us to discover pyrido[2,3-e]tetrazolo[1,5-a]pyrazine analogue 48 as a novel chemotype of a potent and highly selective H4R antagonist. Importantly, orally administered compound 48 exhibits remarkable efficacy on antipruritus and anti-inflammation with a favorable pharmacokinetic (PK) profile in several mouse models of AD. Thus, these data strongly suggest that our compound 48 is a promising clinical candidate for treatment of AD.

NOVEL FUSED HETEROCYCLES AND USES THEREOF

This invention relates to novel compounds having the Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment or prophylaxis of H. pylori infection.